Evidence-based prescribing of antidepressants

Area of Science:

• Pharmacology
• Clinical Research
• Evidence-Based Medicine

Background:

• Formal clinical trials for antidepressants establish efficacy but may not reflect real-world prescribing conditions.
• Rigorous trial methodologies limit observation of co-morbid disorders, side effects, and off-label use.
• A gap exists between controlled trial data and the complexities of everyday clinical practice.

Purpose of the Study:

• To highlight the value of post-marketing surveillance and real-world data in antidepressant research.
• To introduce the concept of "prescribing-based evidence" as a complement to traditional evidence-based recommendations.
• To illustrate how post-marketing studies can expand understanding of drug efficacy and indications.

Main Methods:

• Review of post-marketing studies, including observations, case studies, open trials, and small comparative trials.
• Analysis of data from real-world prescribing scenarios.
• Case illustration using milnacipran, a serotonin and noradrenaline reuptuptake inhibitor (SNRI).

Main Results:

• Post-marketing studies provide crucial information on responder characteristics and side effect acceptance.
• These studies offer insights into drug use in patients with co-morbidities and off-label indications.
• Intense post-marketing study of milnacipran, particularly in Japan, revealed efficacy in chronic pain conditions like fibromyalgia.

Conclusions:

• Prescribing-based evidence is a vital complement to evidence-based recommendations derived from clinical trials.
• Post-marketing surveillance can lead to the discovery of unforeseen therapeutic applications for existing drugs.
• Studies on milnacipran exemplify how real-world data enhances understanding of antidepressant utility beyond initial licensing.